Astria Therapeutics

Latest Merger & Acquisition Life Science News

Taro Pharmaceutical Shareholders Approve Merger with Sun Pharma

May 23
Last Trade: 42.69 -0.06 -0.14

MUMBAI, India and NEW YORK, May 23, 2024 /CNW/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro...Read more

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

May 22
Last Trade: 217.81 -0.25 -0.11

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3 Proposed acquisition builds on Biogen capabilities...Read more

Johnson & Johnson to Acquire Proteologix to Lead in Atopic Dermatitis Treatment

May 16
Last Trade: 146.97 -2.73 -1.82

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD) Includes bispecific antibodies targeting proven disease pathways and offers the potential to provide best-in-disease therapeutics for people with moderate to severe AD and asthma These pipeline additions demonstrate the Company’s strategic approach to build a portfolio of differentiated...Read more

Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies

May 13
Last Trade: 1.98 -0.04 -1.98

ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologies EP (APT), a privately-held Minnesota-based developer of innovative electrophysiology catheters. “Acquiring APT provides...Read more

Reneo Pharmaceuticals and OnKure Announce Proposed Merger

May 13
Last Trade: 1.66 -0.07 -4.05

Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026 IRVINE, Calif., and BOULDER, Colo., May 13, 2024 (GLOBE NEWSWIRE) -- Reneo...Read more

Invitae Receives Court Approval for Sale to Labcorp

Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases Key milestone reached in Invitae's Chapter 11 process BURLINGTON, N.C. and SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical genetics company,  announced today that the United States Bankruptcy...Read more

EUDA Health Expands into Direct Selling Holistic Wellness Products with Acquisition of CK Health

SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of holistic wellness consumer products in Malaysia. Under the terms of the acquisition agreement, EUDA has...Read more

TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies

May 6
Last Trade: 1.13 -0.01 -0.88

Acquisition target has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors EDINBURGH, Scotland, May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution...Read more

U.S. Physical Therapy Announces Acquisitions

The Company Acquired an Industrial Injury Prevention Business and a Physical Therapy Practice HOUSTON / May 01, 2024 / Business Wire / U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (“IIP”), announced the acquisition of an IIP services business by one of its primary IIP companies, Briotix Health Limited...Read more

Harmony Biosciences Acquires Epygenix Therapeutics, Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets

April 30
Last Trade: 29.95 0.60 2.04

Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026 Plan to Initiate Phase 3 Trial for Lennox-Gastaut Syndrome in Second Half of 2024 Potential Billion Dollar Plus Market Opportunity in Rare Epilepsy PLYMOUTH MEETING, Pa., April 30, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY), today announced the...Read more

908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering

April 30
Last Trade: 6.48 -0.09 -1.37

Adds optical spectroscopy to the company’s technology platform for point-of-need applications BOSTON / Apr 30, 2024 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biochemical analysis, announces that it has completed the acquisition of privately-held RedWave Technology, a leading provider of portable FTIR spectroscopic analyzers for rapid chemical...Read more

Hologic to Acquire Endomagnetics, a Breast Surgical Guidance Company

April 29
Last Trade: 73.80 -0.19 -0.26

MARLBOROUGH, Mass. / Apr 29, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments. “Endomag’s suite of solutions complements our existing breast...Read more

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion

April 29
Last Trade: 25.51 0.01 0.04

Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO Pharmaceutical’s Pipeline and Accelerate Global Reach WALTHAM, Mass. / Apr 29, 2024 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to...Read more

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

April 23
Last Trade: 57.31 -0.14 -0.24

EP262, a first-in-class oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist with the potential to treat a broad range of inflammatory disorders, has demonstrated proof-of-mechanism in chronic inducible urticaria and is in a Phase 2 study for chronic spontaneous urticaria EP547 is a first-in-class oral MRGPRX4 antagonist with the potential to treat cholestatic pruritus and other conditions with severe pruritus Acquisition...Read more

Bruker to Acquire the NanoString Business in an Asset Deal

April 22
Last Trade: 77.25 0.55 0.72

NanoString is an Established Leader and Valuable Innovator in Gene Expression Profiling and Spatial Transcriptomics for Scientific and Clinical Research in Healthcare BILLERICA, Mass. / Apr 22, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for...Read more

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

April 11
Last Trade: 7.41 -0.03 -0.40

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials...Read more

Vertex Pharmaceuticals Enters Into Agreement to Acquire Alpine Immune Sciences

April 10
Last Trade: 456.95 6.15 1.36

Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies  Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024  Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway  Alpine’s protein engineering...Read more

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

April 10
Last Trade: 3.08 0.00 0.00

Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Shareholders of Nuvation Bio and AnHeart Therapeutics immediately prior to close now own approximately 67% and 33%, respectively, of Nuvation Bio on a fully diluted basis NEW YORK / Apr 10, 2024 / Business Wire / Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling...Read more

Johnson & Johnson to Acquire Shockwave Medical

April 5
Last Trade: 146.97 -2.73 -1.82

Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech’s Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To...Read more

TC Biopharm Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies

April 4
Last Trade: 1.13 -0.01 -0.88

EDINBURGH, Scotland, April 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent as part of its M&A strategy aimed at expanding its therapeutic platform and leveraging NK (natural killer)...Read more

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

April 3
Last Trade: 28.00 -1.34 -4.57

Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-generation, potential best-in-class Topo1 ADC targeting folate receptor alpha (FRα) in development for the treatment of ovarian...Read more

Asensus Surgical Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG

April 3
Last Trade: 0.24 -0.0036 -1.47

RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient, today announced that it has entered into a non-binding letter of intent (the “letter of intent”) with KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company (“KARL STORZ”)...Read more

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

April 3
Last Trade: 3.39 0.13 3.99

Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing...Read more

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

April 3
Last Trade: 0.17 0.01 7.01

TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway $31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025 TuHURA's first-in-class bifunctional Antibody Drug Conjugates...Read more

Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs

April 2
Last Trade: 0.66 0.0046 0.70

BOSTON, April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries. Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune...Read more

Viemed Healthcare Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

April 2
Last Trade: 7.06 0.16 2.32

LAFAYETTE, La., April 02, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health (“EAH”), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to...Read more

Onconova Therapeutics and Trawsfynydd Therapeutics Announce Business Combination to Form Traws Pharma a Best-in-Class Virology and Oncology Company

April 2
Last Trade: 1.00 0.00 0.00

Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines Funding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low grade endometriod endometrial cancer...Read more

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt

April 2
Last Trade: 0.03 -0.005 -14.29

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that it...Read more

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics, Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

April 2
Last Trade: 2.04 -0.03 -1.44

Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation MOUNTAIN VIEW, Calif. / Apr 02, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered...Read more

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

April 1
Last Trade: 79.85 0.52 0.66

With the addition of MIM Software, GE HealthCare aims to provide clinicians and healthcare systems with increasingly integrated and automated solutions, meeting the evolving needs of providers, and reinforcing a shared legacy of advanced patient care solutions Portfolio additions include AI-enabled image analysis and workflow tools spanning multiple care areas, including oncology, urology, neurology, and cardiology CHICAGO / Apr 01,...Read more

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI, March 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered...Read more

Avalo Therapeutics Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

March 27
Last Trade: 13.10 1.95 17.49

Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md.,...Read more

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

March 26
Last Trade: 14.22 -0.12 -0.84

BOTHELL, Wash. / Mar 26, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, Inc. “AL102 is a high-quality asset that complements our existing pipeline of targeted cancer therapies,” said Clay B. Siegall,...Read more

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

March 25
Last Trade: 136.04 0.47 0.35

Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse...Read more

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

March 25
Last Trade: 3.08 0.00 0.00

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation, potentially best-in-class ROS1 inhibitor with Breakthrough Therapy Designations currently completing two pivotal studies for the treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC) Acquisition also adds safusidenib, a...Read more

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

March 25
Last Trade: 22.93 0.00 0.00

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class, oral...Read more

Gilead Sciences Completes $4.3 Billion Acquisition of CymaBay Therapeutics

March 22
Last Trade: 65.68 -0.49 -0.74

Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases FOSTER CITY, Calif. / Mar 22, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay’s investigational lead product...Read more

AstraZeneca to acquire Fusion Pharmaceuticals to accelerate the development of next-generation radioconjugates to treat cancer

March 19
Last Trade: 78.54 0.36 0.46

Includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities WILMINGTON, Del. / Mar 19, 2024 / Business Wire / AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a...Read more

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

March 18
Last Trade: 41.24 -0.30 -0.72

KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications PRINCETON, N.J. / Mar 18, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global...Read more

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

March 18
Last Trade: 0.34 -0.0048 -1.39

Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the treatment of diabetic foot osteomyelitis (“DFO”) Financing of $50 million will be used to advance the two lead product candidates through Phase 2 clinical readouts in 2025 CAMBRIDGE, Mass. and NESS ZIONA, Israel,...Read more

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

March 14
Last Trade: 2.57 0.00 0.00

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage, Ph.D., named President and Chief Operating Officer A strategic U.S. commercial license agreement with a global pharmaceutical company and concurrent institutional investment expected to close in 2H’24 Conference Call...Read more

eMed completes tender offer for all outstanding shares of Science 37

March 12
Last Trade: 5.75 0.00 0.00

MIAMI, March 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin Merger Sub Corporation ("Purchaser"), for all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") at a price of USD 5.75 per share. Continental Stock Transfer & Trust Company,...Read more

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

March 12
Last Trade: 8.36 -0.03 -0.36

TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the “Transaction”) at their respective special meetings held today. The specific voting results were as follows: Aeterna...Read more

Merck Completes Acquisition of Harpoon Therapeutics

March 11
Last Trade: 129.49 -1.60 -1.22

Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager RAHWAY, N.J. / Mar 11, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of...Read more

Johnson & Johnson Completes Acquisition of Ambrx Biopharma

March 7
Last Trade: 146.97 -2.73 -1.82

Acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics NEW BRUNSWICK, N.J. / Mar 07, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic...Read more

Bruker Announces Closing of Chemspeed Technologies AG Acquisition

March 7
Last Trade: 77.25 0.55 0.72

BASEL, Switzerland / Mar 07, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider of automated laboratory R&D and QC workflow solutions. This acquisition, first announced in January 2024, marks another significant milestone in Bruker’s expansion in vendor-agnostic scientific software, R&D and QC digitalization,...Read more

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

March 6
Last Trade: 0.34 -0.0048 -1.39

Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the treatment of diabetic foot osteomyelitis (“DFO”) Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive agreement for a private placement financing of $50 million that will be used to advance...Read more

Aptorum Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding and a Split-off Agreement to Separate its Legacy Business

March 6
Last Trade: 4.59 0.58 14.46

NEW YORK & LONDON / Mar 06, 2024 / Business Wire / Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”). The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of...Read more

Ambrx Biopharma Shareholders Approve Acquisition by Johnson & Johnson

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the...Read more

Haemonetics Announces Definitive Agreement to Acquire Attune Medical

March 5
Last Trade: 88.34 -0.30 -0.34

BOSTON, March 5, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical products and solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to acquire privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, the only FDA-cleared temperature regulation...Read more

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

March 5
Last Trade: 1.94 0.08 4.30

BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC: PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction....Read more

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

February 28
Last Trade: 77.25 0.55 0.72

ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral...Read more

Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers

February 28
Last Trade: 0.66 0.0046 0.70

BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines and was backed by Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, and S32. The acquisition is intended to...Read more

Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers

February 28
Last Trade: 0.66 0.0046 0.70

BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Proof Diagnostics, an innovative life sciences tools, diagnostics and computational discovery company which uncovered genome engineering tools for both therapeutic and diagnostics applications while developing a smart, portable system for the detection of...Read more

Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx

February 28
Last Trade: 1.10 0.00 0.00

Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and...Read more

Veradigm to Acquire ScienceIO

February 27
Last Trade: 7.55 0.74 10.87

Veradigm to Leverage ScienceIO’s Leading Healthcare Artificial Intelligence (AI) Platform on the Company’s Large-Scale, High-Quality Data Set to Build Advanced, Private Language Models for Healthcare Expected to Provide Highly Differentiated and More Advanced Products to Veradigm Customers Acquisition Will Help Accelerate Platform Improvements Across the Veradigm Network, including the Provider, Payer and Life Sciences...Read more

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

February 26
Last Trade: 41.24 -0.30 -0.72

Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS PRINCETON, N.J. / Feb 26, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. “We are excited...Read more

NGM Biopharmaceuticals Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group

February 26
Last Trade: 1.54 0.00 0.00

NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transaction Based on a thorough exploration and review of strategic and financial alternatives, a Special Committee of independent and disinterested directors unanimously recommends...Read more

DarioHealth acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions

February 21
Last Trade: 1.76 0.16 10.00

Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross margins and expected to accelerate path to profitability Concurrent with the acquisition Dario prices $22.4 million equity financing Company to host conference call today at 8:30am ET. Dial-in and replay information below NEW YORK, Feb. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the...Read more

Freeline Therapeutics: Acquisition of Freeline by Syncona Becomes Effective

February 20
Last Trade: 6.48 0.00 0.00

LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that, in connection with Syncona’s acquisition of Freeline by way of a scheme of arrangement (the “Scheme”), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the “Scheme Circular”) has been...Read more

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

February 16
Last Trade: 24.91 -0.17 -0.68

EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0.2527 per share (together with the Base Price, the Cash Amount) at the closing of the merger plus a non-transferable contingent value right...Read more

AbbVie Completes Acquisition of ImmunoGen

February 12
Last Trade: 157.06 -1.20 -0.76

Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand...Read more

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

February 12
Last Trade: 65.68 -0.49 -0.74

Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024  Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC  Acquisition Expands Gilead’s Long-Standing Commitment to Patients with Liver Diseases  FOSTER CITY, Calif. & NEWARK, Calif. / Feb 12, 2024 /...Read more

eMed commences tender offer for Science 37

February 12
Last Trade: 5.75 0.00 0.00

MIAMI, Feb. 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer to purchase all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") for a price of $5.75 per share (the "Offer"). The Offer is being made upon the terms and...Read more

Bruker Acquires Nanophoton, a Japanese Technology Leader in Research Raman Microscopy with 20 Years of Experience

February 7
Last Trade: 77.25 0.55 0.72

Nanophoton Strengthens Bruker’s Portfolio of Molecular Microscopy Research Solutions OSAKA, Japan / Feb 07, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced Raman microscopes, serving academic and industrial research customers,...Read more

Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems

February 6
Last Trade: 77.25 0.55 0.72

Acquisition Complements Bruker’s Preclinical Imaging Portfolio with In-Vivo Optical Imaging TUCSON, Ariz. / Feb 06, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that it has acquired Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems. This acquisition fills a gap in the technology and product portfolio of the Bruker BioSpin Preclinical Imaging (PCI) division, broadening...Read more

Merck Animal Health to Acquire Elanco’s Aqua Business

February 5
Last Trade: 129.49 -1.60 -1.22

Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries Complements Merck Animal Health’s broad portfolio of veterinary pharmaceuticals, vaccines and technology solutions RAHWAY, N.J. / Feb 05, 2024 / Business Wire / Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a...Read more

Novo Holdings to Acquire Catalent

February 5
Last Trade: 54.82 0.17 0.31

Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024 COPENHAGEN, Denmark & SOMERSET, N.J. / Feb 05, 2024 / Business Wire / Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the...Read more

VitalHub Announces Acquisition of BookWise Solutions

February 5
Last Trade: 7.00 0.03 0.43

Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - VITALHUB CORP. (TSX: VHI) (OTCQX: VHIBF) (the "Company" or "VitalHub") is pleased to announce that it has acquired (the "Acquisition") BookWise Solutions Limited ("BookWise"), a company incorporated and existing under the laws of England and Wales. BookWise offers specialist scheduling software for healthcare and corporate organisations ranging from general room booking software to...Read more

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

February 1
Last Trade: 23.16 -0.11 -0.47

SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. Myriad’s Precise Tumor...Read more

HEALWELL AI Completes Acquisition of Intrahealth

February 1
Last Trade: 1.72 0.00 0.00

HEALWELL has completed the previously announced acquisition of Intrahealth, a SaaS based enterprise class multi-national EHR (Electronic Health Record) provider supporting approximately 15,000 clinicians providing care for millions of patients from small clinics to large health delivery organizations in its global network across Canada, Australia and New Zealand. Intrahealth is expected to generate over $12 million in revenues in 2024,...Read more

Cardinal Health to acquire Specialty Networks and its PPS Analytics platform, a technology enabled multi-specialty group purchasing and practice enhancement organization in urology, rheumatology and gastroenterology

January 31
Last Trade: 96.39 0.34 0.35

Transaction creates increased clinical and economic value for 11,500 specialty providers, including more than 7,000 physicians across 1,200 independent physician practices Transaction creates platform for Cardinal Health expansion across specialty therapeutic areas Transaction enhances capabilities of Cardinal Health Specialty and supports ongoing build of Navista™ Network DUBLIN, Ohio, Jan. 31, 2024 /PRNewswire/ -- Cardinal...Read more

Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies

January 31
Last Trade: 1.69 0.06 3.68

Repositioning to a rapidly expanding biosensor market with potential for significant growth for the company as part of a revised strategy under our new management Upfront payment of $12.5 million cash and 9 million ADSs Strengthened investment relationship with Perceptive Advisors with the entry into an increased senior secured term loan credit facility with lower interest rates and Perceptive Advisors taking an approximately 20%...Read more

Regeneron Pharmaceuticals Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

January 30
Last Trade: 985.02 4.45 0.45

TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired...Read more

AVROBIO and Tectonic Therapeutic Announce Merger

January 30
Last Trade: 1.51 0.10 7.09

Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 million in cash and cash equivalents at close to provide cash runway into mid-2027 Funding is expected to...Read more

Aditxt Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

January 30
Last Trade: 2.04 -0.03 -1.44

The global EEG devices market was valued at $1.06 billion in 2022 and is anticipated to expand at a CAGR of 10.2% from 2023 to 2030 RICHMOND, Va. / Jan 30, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced the acquisition of a portfolio of EEG brain monitoring technologies and devices formerly owned...Read more

Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment

January 29
Last Trade: 5.75 0.00 0.00

RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today announced that it has entered into a definitive merger agreement to be acquired by eMed, LLC (“eMed”), the leader in on-demand virtual care and treatment for consumers. With the most authoritative in-home testing and treatment solution available...Read more

Bruker Announces Agreement to Acquire Chemspeed

January 25
Last Trade: 77.25 0.55 0.72

Chemspeed Accelerates Bruker’s Laboratory Automation and Digitalization Drive BASEL, Switzerland / Jan 25, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research,...Read more

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio

January 23
Last Trade: 41.24 -0.30 -0.72

PRINCETON, N.J. / Jan 23, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb. “The closing of the Mirati transaction is a significant milestone in our...Read more

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

January 23
Last Trade: 0.89 0.02 2.29

NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial Program developed by Florida Biotechnologies, Inc. & the University of Miami’s Bascom Palmer Eye Institute NAYA continuing to implement acquisition roll-up of clinical and commercial assets in oncology, regenerative medicine, and fertility NAYA expects to close its previously announced merger...Read more

Natera Acquires Reproductive Health Assets from Invitae

January 22
Last Trade: 109.51 2.00 1.86

AUSTIN, Texas / Jan 22, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical genetics company, certain assets relating to Invitae’s non-invasive prenatal screening and carrier screening business. Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the transaction includes...Read more

R1 RCM Completes Acquisition of Acclara, Providence’s Modular Services Business

January 17
Last Trade: 12.48 0.34 2.80

Company Enters 10-Year Agreement to Provide Comprehensive Revenue Cycle Management Services to Providence Company to Release Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Outlook on February 27, 2024 MURRAY, Utah, Jan. 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of...Read more

Taro Pharmaceutical Announces Merger Agreement with Sun Pharmaceutical

January 17
Last Trade: 42.69 -0.06 -0.14

Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023 MUMBAI, India and NEW YORK, Jan. 17, 2024 /CNW/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that they...Read more

Biote to Purchase Asteria Health

January 17
Last Trade: 6.35 0.45 7.63

Strategic and accretive transaction enables vertical integration of hormone product manufacturing IRVING, Texas / Jan 17, 2024 / Business Wire / biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a...Read more

GSK Enters Agreement to Acquire Aiolos Bio

January 9
Last Trade: 45.12 -0.03 -0.07

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway AIO-001 could redefine the standard-of-care with dosing every six months AIO-001 has potential to expand GSK’s respiratory biologics portfolio to reach a broader portion of asthma patients SAN FRANCISCO & LONDON / Jan 09, 2024 / Business Wire / GSK plc (LSE/NYSE: GSK) and Aiolos...Read more

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

January 8
Last Trade: 146.97 -2.73 -1.82

Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson's Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics NEW BRUNSWICK, N.J. / Jan 08, 2024 / Business Wire / Johnson & Johnson...Read more

Boston Scientific Announces Agreement to Acquire Axonics

January 8
Last Trade: 75.63 1.25 1.68

Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass., Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to...Read more

GE HealthCare announces agreement to acquire MIM Software

January 8
Last Trade: 79.85 0.52 0.66

The anticipated acquisition aligns to GE HealthCare’s precision care strategy with the goal of strengthening the company’s digital solutions across care pathways MIM Software provides AI-enabled image analysis and workflow tools across multiple care areas, including oncology, urology, neurology, and cardiology Today’s agreement reinforces GE HealthCare’s commitment to integrate medical imaging products in order to deliver more precise,...Read more

Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System

January 8
Last Trade: 141.28 1.24 0.89

Transaction to broaden access to innovative, quality diagnostic information services for providers and patients SECAUCUS, N.J., Jan. 8, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has acquired select assets of Steward Health Care System's outreach laboratory services business serving patients and physicians in Pennsylvania and...Read more

OrthoPediatrics Announces Acquisition of Boston Orthotics & Prosthetics

January 8
Last Trade: 32.54 0.81 2.55

Combined organizations have helped more than 1 million kids Expands Specialty Bracing Division with pediatric orthotic management business offering leading technology and pediatric care through dedicated clinics Closes $80 million debt financing to support acquisition and future business requirements WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS),...Read more

Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock


Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...